ArticleTrends in microbiology2021
Endocannabinoids Attenuate the Virulence of Certain Enteropathogenic Bacteria.
Article in Trends in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- "Elucidating the immunomodulatory role of endocannabinoids in intervertebral disc degeneration".European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mammalian endocannabinoid system modulates gastrointestinal physiology and immunity via lipid hormones (endocannabinoids). Ellermann et al. have recently revealed the effect of the endocannabinoid, 2-arachidonoyl glycerol (2-AG) on intestinal infection. They show that 2-AG directly modulates bacterial function by antagonizing the provirulence receptor QseC, thereby protecting mice against enteric infection. The endocannabinoid system has already been identified as a promising target in the treatment of inflammatory bowel diseases, but these new findings raise questions about the possible benefits of using cannabinoids to treat intestinal bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.